Monoclonal antibodies (mAbs) are characterized by their vast diversity in both structure and activity. As such, researchers may evaluate hundreds of mAbs while identifying their best binders. But this selection process can take months as conventional biologics discovery techniques do not include tools that can truly assess mAb biophysical diversity that directly affects specificity and affinity. With REmAb®’s next generation protein sequencing platform, mAb leads can be analyzed down to the amino acid level, including PTMs for targeted and controlled development in parallel.
Polyclonal antibodies (pAbs) are well used in drug discovery research because they recognize and bind many different epitopes of a single antigen. However, because the identity and sequence of each antibody in the mixture is unknown, polyclonal mixtures are difficult to work with. Current biologics discovery methods are indirect, expensive and time consuming. The advent of Polyclonal Antibody sequencing allows researchers to directly access high-affinity antibodies from the native immune response, derive their amino acid sequences and express a set of mAbs that perform as well or better than the original polyclonal mixture. Polyclonal antibody sequencing is the most direct method for therapeutic antibody discovery.